Mandate

Vinge advises Baseload Capital in connection with its 53 MEUR Series B financing round

September 04, 2024

Vinge has advised Baseload Capital Holding AB in connection with the closing of its 53 MEUR Series B financing round. The round was led by an investment from infrastructure fund ENGF. The main investor behind ENGF is Ingka Investments, the investment arm of Ingka Group. Other shareholders participating in this round include energy technology company Baker Hughes (whose investment was announced in 2023), NEFCO, Breakthrough Energy Ventures and Gullspång Invest.

Baseload Capital is a leading investment entity dedicated to advancing geothermal energy deployment globally. Through the establishment of operating companies in global locations, Baseload Capital partners with local communities and power providers to commission, permit and build Baseload Capital-funded geothermal power plants. Baseload Capital and its Baseload Power subsidiaries operate in mature geothermal markets like Iceland, the US, and Japan, as well as in emerging markets like Taiwan. As one of the first European investments by Breakthrough Energy Ventures (BEV), Baseload Capital also carries a certain quality mark as BEV only invests in companies that can reduce emissions by at least half a gigaton of greenhouse gases. 

Vinges team consisted primarily of Maria Dahlin Kolvik, Gustav Wahlberg and Måns Håkansson.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025